Patients (n) | 499 | |||
---|---|---|---|---|
Gender | Female n (%) | 333 (66.7) | ||
median (range) | n (%) | |||
Age (years) | at blood collection | 11 (3–22) | 3–10 years | 11–22 years |
228 (45.7) | 270 (54.3) | |||
at study inclusion | 7 (< 1–17) | |||
at onset of disease | 6.0 (< 1–16.4) | |||
median (range) | n (%) | |||
Disease duration at time of blood collection (years) | 4.4 (0.9–14.1) | < 4.5 years | > 4.5 years | |
256 (51.3) | 240 (48.1) | |||
Disease activity score (cJADAS-10) | 3.0 (0.5–25) | |||
no data | n = 164 | |||
n (%) | ||||
Treatment | ever before blood collection | at time of blood collection | ||
csDMARDs | 427 (85.6) | 274 (54.9) | ||
bDMARDs | 206 (41.3) | 140 (28.1) | ||
Glucocorticoide therapy | 442 (84.6) | 82 (16.4) | ||
n (%) | ||||
JIA categories | systemic arthritis | 16 (3.2) | ||
oligoarthritis, extended | 49 (9.8) | |||
oligoarthritis, persistent | 168 (33.7) | |||
psoriatic arthritis | 27 (5.4) | |||
enthesitis-related arthritis | 52 (10.4) | |||
polyarthritis, seropositive | 10 (2.0) | |||
polyarthritis, seronegative | 142 (28.5) | |||
undifferentiated arthritis | 34 (6.8) | |||
no data | 1 (0.2) | |||
Physician reported ANA positive patients at inclusion | 310 (62.1) |